Sustained-release microsphere preparation comprising tirzepatide or pharmaceutically acceptable salt thereof and method for preparing same

Sustained-release microspheres with high terzepatide content and biodegradable polymers address the low bioavailability and injection challenges of terzepatide, providing prolonged efficacy and reduced side effects by controlling initial drug release, enhancing bioavailability and patient comfort.

WO2024248572A1PCT designated stage expired Publication Date: 2024-12-05G2GBIO INC
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
PCT/KR2024/007594
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-06-02
Filing Date
2024-06-03
Publication Date
2024-12-05

AI Technical Summary

Technical Problem

The administration of terzepatide, an antidiabetic drug, faces challenges due to low bioavailability when encapsulated in microspheres, requiring high doses that are difficult to inject subcutaneously, leading to pain and inflammatory reactions.

Method used

Development of sustained-release microspheres with a high terzepatide content (8% by weight) and an initial release inhibitor, using biodegradable polymers like polylactide and polyglycolide, which suppress initial drug release, ensuring long-term pharmacological effects with reduced dosing and minimized side effects.

Benefits of technology

The formulation achieves high bioavailability and prolonged efficacy for over a month, reducing the dosage and minimizing pain and inflammatory reactions at the administration site, while maintaining effective glycemic control.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure KR2024007594_05122024_PF_FP_ABST
    Figure KR2024007594_05122024_PF_FP_ABST
Patent Text Reader

Abstract

The present invention relates to a pharmaceutical composition which, by comprising sustained-release microspheres which consist of tirzepatide or a pharmaceutically acceptable salt thereof, an initial-burst inhibitor, and a biodegradable polymer, does not undergo rapid initial burst of a drug, has a high content of the drug relative to the particle size, and has high bioavailability, thus being able to minimize the patient's pain and inflammatory response that may occur when administered to the human body, and thus is effective in the prevention or treatment of diabetes, beta-cell dysfunction, hypertension, hyperlipidemia, obesity, and non-alcoholic steatohepatitis.
Need to check novelty before this filing date? Find Prior Art

Description

Sustained-release microsphere formulation comprising terzepatide or a pharmaceutically acceptable salt thereof and method for preparing the same

[0001] The present invention relates to a pharmaceutical composition comprising sustained-release microspheres containing a high content of terzepatide or a pharmaceutically acceptable salt thereof, and a method for producing the sustained-release microspheres.

[0002] Tirzepatide, sold under the brand name Mounjaro, is an antidiabetic drug used to treat type 2 diabetes. It is administered once a week via subcutaneous injection.

[0003] The most common side effects include nausea, vomiting, diarrhea, decreased appetite, constipation, upper abdominal discomfort, and abdominal pain.

[0004] Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are hormones involved in blood sugar regulation. After eating, these hormones are secreted from intestinal cells, inducing insulin secretion. Terzepatide is known as a GIP analogue that improves blood sugar control by activating both GLP-1 and GIP receptors.

[0005]

[0006] Terzepatide was approved for medical use in the United States in May 2022, the European Union in September 2022, Canada in November 2022, and Australia in December 2022. The U.S. Food and Drug Administration (FDA) considers it a first-in-class drug.

[0007] For the effective monotherapy of terzepatide, it is necessary to develop a technology to ensure long-term, effective pharmacological effects. Therefore, the inventors of the present invention have developed a technology to encapsulate terzepatide in microspheres made of biodegradable polymers for long-term dissolution. However, in this case, the bioavailability of terzepatide encapsulated in the microspheres is low, or the drug content within the microspheres is low, so large doses of microspheres must be administered to achieve long-term, effective pharmacological effects. However, administering large doses of microspheres in vivo poses challenges, such as the difficulty of subcutaneous injection, making it difficult for patients to administer the drug directly (self-administer), and the potential for significant increases in pain and inflammation at the injection site.

[0008] The present invention has been proposed to solve the above problems, and its purpose is to provide a pharmaceutical composition comprising sustained-release microspheres comprising a high content of terzepatide, terzepatide or a pharmaceutically acceptable salt thereof exhibiting long-term stable drug release characteristics, a biodegradable polymer, and an early-release inhibitor, and a method for producing the sustained-release microspheres.

[0009] The present invention is described in detail below.

[0010]

[0011] The term "one or more kinds" in the present invention means "number" corresponding to one or more. In the present invention, when a certain configuration is one or more kinds, it may preferably be one kind, two or more kinds, three or more kinds, one to three kinds, or one to two kinds, but is not limited thereto. The term "one or more kinds" may be used interchangeably with the term "one or more" in the present invention.

[0012]

[0013] To achieve the above purpose,

[0014] In one aspect, the present invention provides a pharmaceutical composition comprising sustained-release microspheres of terzepatide, which comprise a biodegradable polymer, wherein the content of terzepatide is at least 8 wt% as terzepatide based on the total weight of the microspheres, and an early-release inhibitor is at 5 ppm to 2000 ppm based on the weight of terzepatide.

[0015] In another aspect, the biodegradable polymer is polylactide (PLA), polyglycolide (PGA), polylactide-co-glycolide (PLGA), polydioxanone, polycaprolactone (PCL), polylactide-co-glycolide-co-caprolactone (PLGC), polylactide-co-hydroxymethyl glycolide (PLGMGA), polyalkylcarbonate, polytrimethylenecarbonate (PTMC), polylactide-co-trimethylenecarbonate (PLTMC), A polymer selected from the group consisting of block copolymers of polyhydroxybutyric acid (PHB), polyhydroxybutyrate-co-hydroxyvalerate (PHBV), polyorthoester, polyanhydride, polyanhydride-co-imide, polypropylene fumarate, pseudo polyaminoacid, polyalkyl cyanoacrylate, polyphosphazene, polyphosphoester polysaccharide and poly(butylene succinate lactide) (PBSLA); simple mixtures of two or more thereof; A copolymer of the above polymer and polyethylene glycol (polyethylenglycol, PEG);And it may be at least one selected from the group consisting of a polymer-sugar complex in which the polymer or copolymer is combined with a sugar.;

[0016] In another aspect, the pharmaceutically acceptable salt of the above terzepatide may be the sodium salt, acetate salt, benzoate salt, hydroxynaphthoate salt, napadicylate salt or pamoate salt of terzepatide.

[0017] In another aspect, the biodegradable polymer may be characterized by an intrinsic viscosity of 0.16 to 1.7 dL / g. More specifically, the biodegradable polymer may be characterized by an intrinsic viscosity of poly(lactide-co-glycolide) or polylactide of 0.16 to 1.7 dL / g.

[0018] In another aspect, the average particle size of the microspheres containing the above-described terzepatide or a pharmaceutically acceptable salt thereof and an early release inhibitor may be from 5 μm to 100 μm.

[0019] In another aspect, the microspheres containing the above-described terzepatide or a pharmaceutically acceptable salt thereof and an early release inhibitor may be characterized in that the span value is 1.5 or less.

[0020] In another aspect, the weight of the entire microspheres containing terzepatide or a pharmaceutically acceptable salt thereof and an early release inhibitor included in the pharmaceutical composition is 20 to 1000 mg, 20 to 800 mg, 20 to 600 mg, 20 to 400 mg, 20 to 200 mg, 20 to 100 mg, 30 to 1000 mg, 30 to 800 mg, 30 to 600 mg, 30 to 400 mg, 30 to 200 mg, 30 to 100 mg, 40 to 1000 mg, 40 to 800 mg, 40 to 600 mg, 40 to 400 mg, 40 to 200 mg, 40 to 100 mg, It may be 50 mg to 1000 mg, 50 mg to 800 mg, 50 mg to 600 mg, 50 mg to 400 mg, 50 mg to 200 mg, or 50 mg to 100 mg.

[0021] In another aspect, it may further comprise one or more release controlling agents selected from butyric acid, valeric acid, caproic acid, enanthic acid, caprylic acid, pelargonic acid, capric acid, undecylic acid, lauric acid, tridecylic acid, myristic acid, pentadecylic acid, palmitic acid, heptadecylic acid, stearic acid, nonadecylic acid, behenic acid, arachidic acid, isocrotonic acid, oleic acid, elaidic acid, sorbic acid, linoleic acid, arachidonic acid, benzoic acid, hydroxynaphthoic acid, napadicylic acid, naphthalene sulfonic acid and pamoic acid.

[0022] In another aspect, the microspheres may comprise 10 to 500 mg / kg of Na.

[0023] In another aspect, the microspheres may comprise 1 to 100 mg / kg of P.

[0024] In another aspect, the present invention provides a method for preparing sustained-release microspheres containing terzepatide or a pharmaceutically acceptable salt thereof and an early-release inhibitor.

[0025] In another aspect, the manufacturing method may use a continuous phase including an early release inhibitor.

[0026] In another aspect, any substance that can set the pH of the continuous phase to 7 or higher when dissolved in the continuous phase can be used as the initial release inhibitor.

[0027] In another aspect, the early-release inhibitor may be at least one selected from the group consisting of phosphate salts, hydroxide salts, phosphide salts, phosphite salts, carbonate salts, bicarbonate salts, chromate salts, dichromate salts, oxides, oxalate salts, silicate salts, sulfate salts, sulfide salts, sulfite salts, tartrate salts, tetraborate salts, thiosulfate salts, arsenate salts, arsenite salts, citrate salts, ferricyanide salts, and nitride salts of alkali metals, alkaline earth metals, or ammonium. In another aspect, the early-release inhibitor may be at least one selected from the group consisting of disodium phosphate, dipotassium phosphate, and diammonium phosphate. In another aspect, a pharmaceutical composition comprising sustained-release microspheres comprising a biodegradable polymer and having a terzepatide content of 8 wt% or more as terzepatide based on the total weight of the microspheres and an initial drug release of 10% or less, and a method for preparing the same, are provided.

[0028] A sustained-release pharmaceutical composition comprising terzepatide or a pharmaceutically acceptable salt thereof and an early-release inhibitor according to one manufacturing example of the present invention has the effect of minimizing pain in the patient and side effects at the injection site that may occur during injection by reducing the dosage of microspheres and exhibiting high bioavailability due to the high dosage by suppressing rapid early release by the early-release inhibitor despite containing a high dosage of terzepatide, and also exhibiting high bioavailability and long-term sustained efficacy of more than one month when administered into the body while allowing a reduction in the dosage of microspheres.

[0029] Figures 1a and b are scanning electron microscope photographs confirming the morphological characteristics of microspheres manufactured according to Example 1 and Comparative Example 1, respectively.

[0030] The present invention is described in detail below.

[0031] The present invention comprises, as an active ingredient, terzepatide or a pharmaceutically acceptable salt thereof.

[0032] Tirzepatide is an acylated peptide engineered to activate GIP and GLP-1 receptors, key mediators of insulin secretion that are also expressed in brain regions that regulate food intake. Tirzepatide is designed to be administered subcutaneously once a week.

[0033] The structure of terzepatide is as shown in chemical formula 1 below.

[0034] [Chemical Formula 1]

[0035]

[0036]

[0037] ​Terzepatide may exist in the form of a salt, particularly a pharmaceutically acceptable salt. Any salt commonly used in the art may be used as the salt without limitation. The term "pharmaceutically acceptable salt" of the present invention refers to any and all organic or inorganic addition salts of the compound, which are relatively non-toxic and harmless to patients and have an effective effect, and whose side effects due to the salt do not diminish the beneficial effects of the active ingredient. Specific examples include, but are not limited to, the sodium salt, acetate salt, benzoate salt, hydroxynaphthoate salt, napadisylate salt, or pamoate salt of terzepatide.

[0038] The active ingredient of the present invention, terzepatide or a pharmaceutically acceptable salt thereof, may be in various forms, for example, amorphous or crystalline.

[0039] The pharmaceutical composition according to the present invention has an area under the blood concentration-time curve (AUC) of terzepatide for up to 24 hours after administration. 0-24hr ) is the area under the total blood concentration-time curve (AUC) total ) may be 20% or less, 10% or less, 5% or less, 0.1 to 20%, 1 to 10%, or 1 to 5%.

[0040] The pharmaceutical composition according to the present invention has an area under the blood concentration-time curve (AUC) of terzepatide from the day of administration to the day of the dosing interval. 0-QXM ) is the area under the total blood concentration-time curve (AUC) total) in comparison, for humans it may be 70% or less, 65% or less, 60% or less, 20 to 70%, 20 to 65%, 20 to 60%, 25 to 70%, 25 to 65%, 25 to 60%, 30 to 70%, 30 to 65% or 30 to 60%, and for rats it may be 95% or less, 93% or less, 90% or less, 50 to 95%, 50 to 93%, 50 to 90%, 55 to 95%, 55 to 93%, 55 to 90%, 60 to 95%, 60 to 93%, or 60 to 90%.

[0041] In addition, the pharmaceutical composition according to the present invention may be a pharmaceutical composition comprising sustained-release microspheres in which the content of terzepatide is 8 wt% or more as terzepatide based on the total weight of the microspheres and the initial release of the drug is less than 10% within 24 hours.

[0042]

[0043] The biodegradable polymer included in the sustained-release microspheres of terzepatide included in the pharmaceutical composition according to the present invention includes, but is not limited to, polylactide (PLA), polyglycolide (PGA), poly(lactide-co-glycolide) (PLGA), polydioxanone, polycaprolactone (PCL), polylactide-co-glycolide-co-caprolactone (PLGC), polylactide-co-hydroxymethyl glycolide (PLGMGA), polyalkylcarbonate, polytrimethylenecarbonate (PTMC), A polymer selected from the group consisting of polylactide-co-trimethylenecarbonate (PLTMC), polyhydroxybutyric acid (PHB), polyhydroxybutyrate-co-hydroxyvalerate (PHBV), polyorthoester, polyanhydride, polyanhydride-co-imide, polypropylene fumarate, pseudo polyaminoacid, polyalkyl cyanoacrylate, polyphosphazene, polyphosphoester, polysaccharide, and poly(butylene succinate lactide) (PBSLA).It is selected from the group consisting of a simple mixture of two or more of the above-mentioned selected polymers, a copolymer of the above-mentioned polymer and polyethylene glycol (Polyethylenglycol, PEG), and a polymer-sugar complex in which the above-mentioned polymer or copolymer is bound to a sugar.

[0044] In addition, the biodegradable polymer may be a simple mixture of two or more (i.e., a simple mixture including two or more of the polymers selected from the above), which may include two or more different types of polymers among the non-limiting examples of the polymers, or may be a combination or blend of the same type of polymers, but may be a combination of polymers of the same type having different intrinsic viscosities and / or monomer ratios (e.g., a combination or blend of two or more poly(lactide-co-glycolide) having different intrinsic viscosities), or may be a polymer of the same type having different terminal groups (e.g., a terminal group of an ester or a terminal group of an acid).

[0045] In one specific embodiment, the pharmaceutical composition according to the present invention may include microspheres containing two or more types of the biodegradable polymers described above. In another specific embodiment, the pharmaceutical composition according to the present invention may include two or more types of microspheres each containing one or more types of two or more polymers selected from the biodegradable polymers described above.

[0046] The above biodegradable polymer may be a biodegradable polymer having an intrinsic viscosity of 0.16 to 1.7 dL / g, 0.2 to 1.3 dL / g, or 0.24 to 1.2 dL / g, taking into account factors such as the release characteristics of the drug and the manufacturing process. The above intrinsic viscosity refers to that measured at a concentration of 0.1% (w / v) in chloroform at 25°C using an Ubbelohde viscometer.

[0047] For the above polylactide-co-glycolide, the molar ratio of lactide to glycol in the copolymer may be 40:60 to 90:10, 45:55 to 85:15, or 50:50 to 75:25, for example, 45:55, 50:50, 75:25, or 85:15.

[0048] When the intrinsic viscosity of the biodegradable polymer is less than 0.16 dL / g, the molecular weight of the polymer is insufficient, making it difficult to exhibit the sustained-release effect of terzepatide or a pharmaceutically acceptable salt thereof. When the intrinsic viscosity of the biodegradable polymer exceeds 1.7 dL / g, the release of terzepatide or a pharmaceutically acceptable salt thereof may be excessively delayed. In addition, when manufacturing microspheres using a polymer with a high intrinsic viscosity, there is a problem that an excessive amount of manufacturing solvent must be used due to the high viscosity of the polymer, and it is difficult to manufacture reproducible microspheres. Examples of commercially available polymers having the above properties include the Resomer® series from Evonik: RG502H, RG503H, RG504H, RG502, RG503, RG504, RG653H, RG752H, RG753H, RG752S, RG755S, RG750S, RG757S, RG858S, R202H, R203H, R205H, R202S, R203S, R205S, R206S, and R207S; PDL 02A, PDL 02, PDL 04, PDL 05, PDLG 7502A, PDLG 7502, PDLG 7507, PDLG 5002A, PDLG 5002; Examples include PDLG 5004A and PDLG 5004.

[0049] The content of the biodegradable polymer in the sustained-release microspheres containing terzepatide or a pharmaceutically acceptable salt thereof and an early-release inhibitor according to the present invention may be selected as an upper limit of 60 wt% or more, 62 wt% or more, 65 wt% or more, 67 wt% or more, or 70 wt% or more, based on the total weight of the microspheres, and may be selected as a lower limit of 92 wt% or less, 91 wt% or less, 90 wt% or less, 89 wt% or less, or 88 wt% or less, or may be included in a range consisting of a combination of the above upper and lower limits. For example, it may be 60 wt% to 92 wt%, 65 to 90 wt%, or 70 to 88 wt%, but is not limited thereto.

[0050] The content of terzepatide or a pharmaceutically acceptable salt thereof in the sustained-release microspheres containing terzepatide or a pharmaceutically acceptable salt thereof and an early-release inhibitor according to the present invention is preferably 8 wt% or more, 12 wt% or more, 14 wt% or more, 37 wt% or less, 35 wt% or less, or 33 wt% or less as terzepatide based on the total weight of the microspheres. When the content of terzepatide or a pharmaceutically acceptable salt thereof in the microspheres is less than 8 wt% based on terzepatide, the amount of polymer used relative to the drug may be too high, which may lower the bioavailability of terzepatide or a pharmaceutically acceptable salt thereof, and when the content is excessively high, the early release of terzepatide or a pharmaceutically acceptable salt thereof may be increased, which may not be preferable.

[0051] A pharmaceutical composition comprising the western-type microspheres according to the present invention may contain an early-release inhibitor in the microspheres in an amount less than a certain amount.

[0052] In the present invention, the early-release inhibitor is a substance included in the continuous phase to suppress the rapid release of the active ingredient in the microsphere manufacturing process, and is characterized in that it exists in the microsphere according to the present invention in less than a certain amount. The continuous phase refers to a substance that enables the dispersion phase including the active ingredient such as terzepatide and a biodegradable polymer to be dispersed when using an emulsion and solvent extraction evaporation method in the method for manufacturing the microsphere, and in the present invention, it may be an aqueous solution including a surfactant, but is not limited thereto. The early-release inhibitor according to the present invention is included in the continuous phase used in this manufacturing method, and can be included in a certain amount in the microsphere according to the present invention after manufacturing accordingly. Matters regarding the continuous phase can be equally applied to matters described in the method for manufacturing the microsphere according to the present invention described below.

[0053] In a specific embodiment, the initial release inhibitor is present in an amount of 5 ppm or more, 10 ppm or more, 20 ppm or more, 30 ppm or more, 40 ppm or more, 50 ppm or more, 100 ppm or more, 150 ppm or more, 200 ppm or more, 250 ppm or more, 200 ppm or more, 300 ppm or more, 350 ppm or more, 400 ppm or more, 450 ppm or more, 500 ppm or more, 550 ppm or more, 600 ppm or more, 650 ppm or more, 700 ppm or more, 750 ppm or more, 800 ppm or more, 850 ppm or more, 900 ppm or more, 950 ppm or more, 1000 ppm or more, 1100 ppm or more, 1200 ppm or more, based on the total weight of the microparticles. The upper limit may include 1300 ppm or more, 1400 ppm or more, or 1500 ppm or more, and the lower limit may include 2000 ppm or less, 1900 ppm or less, 1800 ppm or less, 1700 ppm or less, 1600 ppm or less, 1500 ppm or less, 1400 ppm or less, 1300 ppm or less, 1200 ppm or less, 1100 ppm or less, 1000 ppm or less, 900 ppm or less, 800 ppm or less, 700 ppm or less, 600 ppm or less, or 500 ppm or less, and the range may be comprised of a combination of the above upper and lower limits. For example, the early release inhibitor may be included in an amount of 5 ppm to 2000 ppm, preferably 10 to 1500 ppm, more preferably 20 to 1000 ppm, and most preferably 20 to 500 ppm, based on the total weight of the microparticles.

[0054] In a specific embodiment, the early-release inhibitor may be any substance that, when dissolved in a continuous phase, allows the pH of the continuous phase to be set to 7 or higher. The early-release inhibitor may be at least one selected from among phosphate salts, hydroxide salts, phosphide salts, phosphite salts, carbonate salts, bicarbonate salts, chromate salts, dichromate salts, oxides, oxalate salts, silicate salts, sulfate salts, sulfide salts, sulfite salts, tartrate salts, tetraborate salts, thiosulfate salts, arsenate salts, arsenite salts, citrate salts, ferricyanide salts, and nitride salts of alkali metals, alkaline earth metals, or ammonium, but is not limited thereto.

[0055] In a specific embodiment, the early release inhibitor may be at least one selected from the group consisting of phosphate salts of two or more alkali metals, carbonate salts of one or more alkali metals, bicarbonate salts of one or more alkali metals, and phosphate salts of two or more ammoniums, but is not limited thereto.

[0056] In a more specific embodiment, the phosphate salt of two or more alkali metals means a phosphate salt containing two or more alkali metal ions, for example, disodium phosphate (Na2HPO4) or dipotassium phosphate (K2HPO4), the bicarbonate salt of one or more alkali metals means a bicarbonate salt containing one or more alkali metal ions, for example, sodium bicarbonate (NaHCO3), the carbonate salt of two or more alkali metals means a carbonate salt containing two or more alkali metal ions, for example, sodium carbonate (Na2CO3), and the phosphate salt of two or more ammonium ions means a phosphate salt containing two or more ammonium ions, for example, diammonium phosphate ((NH4)2HPO4), and these may be used alone or in combination of two or more.

[0057]

[0058] The microspheres containing terzepatide or a pharmaceutically acceptable salt thereof and an early-release inhibitor according to the present invention have an average particle size of 5 μm to 100 μm, 5 μm to 90 μm, 5 μm to 80 μm, 10 μm to 90 μm, 10 μm to 80 μm, 15 μm to 100 μm, 15 μm to 90 μm, 15 μm to 80 μm, 70 μm to 100 μm, 70 μm to 90 μm, 70 μm to 80 μm, 60 μm to 100 μm, 60 μm to 80 μm, 60 μm to 70 μm, 20 μm to 90 μm, 20 μm to 70 μm, 20 μm to 60 μm, 30 μm to 80 It is preferable to have a uniform particle distribution of μm, 30 μm to 60 μm, 40 μm to 70 μm, 40 μm to 50 μm, 30 μm to 40 μm, 20 μm to 30 μm, 5 μm to 30 μm, 5 μm to 20 μm, 10 μm to 20 μm, or 5 μm to 10 μm. The term “average particle size” used in the present invention refers to a particle size corresponding to 50% of the volume % in a particle size distribution curve, which means median diameter and is expressed as D50 or D(v, 0.5).

[0059] If the average particle size of the microspheres containing terzepatide or a pharmaceutically acceptable salt thereof and an early-release inhibitor is less than 5 μm, the release of the terzepatide or a pharmaceutically acceptable salt thereof from the microspheres may be too rapid, which may be undesirable. If the average particle size exceeds 100 μm, the injection needle may become too thick during human administration, which may be undesirable because it may cause pain during injection or the drug may leak out of the injection site after injection.

[0060] The microspheres containing terzepatide or a pharmaceutically acceptable salt thereof and an early-release inhibitor of the present invention preferably have a uniform particle distribution. Microspheres containing terzepatide or a pharmaceutically acceptable salt thereof and an early-release inhibitor having a uniform particle distribution have a smaller deviation during injection and can be administered in a more accurate amount compared to microspheres having a non-uniform particle distribution. The span value of the microspheres containing terzepatide or a pharmaceutically acceptable salt thereof and an early-release inhibitor of the present invention is preferably 1.5 or less. More preferably, the span value is 1.2 or less. More specifically, the span value may be 1.5 or less, 1.2 or less, 0.1 to 1.5, 0.3 to 1.5, 0.5 to 1.5, 0.1 to 1.0, 0.4 to 1.0, 0.6 to 1.0, 0.2 to 0.8, or 0.4 to 0.8. The term “span value” used in the present invention is an indicator representing the uniformity of the particle size of the microspheres, and means a value obtained by the formula of Span value = (Dv0.9-Dv0.1) / Dv0.5. Here, Dv0.1 means the particle size corresponding to 10% of the volume% in the particle size distribution curve of the microspheres, Dv0.5 means the particle size corresponding to 50% of the volume% in the particle size distribution curve of the microspheres, and Dv0.9 means the particle size corresponding to 90% of the volume% in the particle size distribution curve of the microspheres.

[0061] The sustained-release microspheres containing terzepatide or a pharmaceutically acceptable salt thereof and an early-release inhibitor of the present invention are administered by an injection route, for example, subcutaneous injection, and are particularly preferred to release terzepatide for a relatively long period of time because they can be self-administered. Preferably, the sustained-release microspheres in the pharmaceutical composition according to the present invention can release terzepatide or a pharmaceutically acceptable salt thereof for, but not limited to, 1 month or more, 2 months or more, 3 months or more, 1 month to 2 months, 1 month to 3 months, 1 month to 4 months, 1 month to 5 months, 1 month to 6 months, 2 months to 6 months, 2 months to 5 months, 2 months to 4 months, 2 months to 3 months, 3 months to 5 months, or 3 months to 4 months. In addition, the sustained-release microspheres of the present invention containing terzepatide or a pharmaceutically acceptable salt thereof and an early-release inhibitor are preferably released within 24 hours when administered in vivo at a release rate (release amount) of terzepatide or a pharmaceutically acceptable salt thereof with an upper limit of less than 10%, less than 15%, or less than 20%, or at a release rate of 0.001% or more, 0.01% or more, 0.1% or more, or 1% or more, or at a release rate in a range of a combination of the upper and lower limits, although the release pattern is not particularly limited.

[0062] In addition, in the pharmaceutical composition of the present invention, the total amount (total weight) of the sustained-release microsphere formulation comprising the terzepatide or a pharmaceutically acceptable salt thereof and an early-release inhibitor is 30 to 3000 mg, 30 to 2500 mg, 30 to 2000 mg, 30 to 1500 mg, 30 to 1250 mg, 30 to 1000 mg, 60 to 3000 mg, 60 to 2500 mg, 60 to 2000 mg, 60 to 1500 mg, 60 to 1250 mg, 100 to 3000 mg, 100 to 2500 mg, 100 to 2000 mg, 100 to 1500 mg, 200 to 3000 mg, 200 to 2500 mg, 200 The composition may be 1500 mg, 400 mg, 300 mg, 400 mg, 2500 mg, 400 mg, 2000 mg, or 400 mg. By including sustained-release microspheres containing terzepatide or a pharmaceutically acceptable salt thereof and an early-release inhibitor in the above range, the composition according to the present invention not only minimizes inflammatory reactions at the site of administration, but also has the advantage of enabling self-administration by the patient.

[0063] The microspheres comprising terzepatide or a pharmaceutically acceptable salt thereof and an early-release inhibitor included in the composition of the present invention may further comprise a release-controlling agent. Examples of the material used as the release-controlling agent include, but are not limited to, one or more selected from butyric acid, valeric acid, caproic acid, enanthic acid, caprylic acid, pelargonic acid, capric acid, undecylic acid, lauric acid, tridecylic acid, myristic acid, pentadecylic acid, palmitic acid, heptadecylic acid, stearic acid, nonadecylic acid, behenic acid, arachidic acid, isocrotonic acid, oleic acid, elaidic acid, sorbic acid, linoleic acid, arachidonic acid, benzoic acid, hydroxynaphthoic acid, napadicylic acid, naphthalene sulfonic acid, and pamoic acid. Preferably, the release controlling agent may be, but is not limited to, hydroxynaphthoic acid, napadiylic acid or pamoic acid.

[0064]

[0065] The pharmaceutical composition comprising microspheres comprising terzepatide or a pharmaceutically acceptable salt thereof and an early-release inhibitor according to the present invention can be formulated into various forms of preparations, and for example, can be a formulation of a known parenteral administration preparation. Accordingly, the pharmaceutical composition according to the present invention can further comprise a thickener, a stabilizer, an isotonic agent, a surfactant, an excipient, and / or a carrier in addition to the terzepatide or a pharmaceutically acceptable salt thereof and an early-release inhibitor. The usable isotonic agent can be a water-soluble excipient or a sugar such as mannitol, sucrose, sorbitol, trehalose, lactose, sodium chloride, etc., and the thickener can be exemplified by carmellose sodium, carboxymethylcellulose sodium, povidone, etc. In addition, the stabilizer can be sodium dihydrogen phosphate, anhydrous citric acid, sodium hydroxide, sodium chloride, etc.

[0066]

[0067] The pharmaceutical composition according to the present invention can be administered in a therapeutically effective amount of terzepatide, for example, an amount effective for treating diabetes, specifically type 2 diabetes, beta-cell dysfunction, hypertension, hyperlipidemia, obesity, non-alcoholic steatohepatitis, or neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease. The therapeutically effective amount of terzepatide can be assessed by a physician. The pharmaceutical composition according to the present invention comprising terzepatide can be administered once a month to once a quarter. In some embodiments, the monthly dosage of the composition according to the present invention is 5 mg to 500 mg, 5 mg to 400 mg, 5 mg to 300 mg, 5 mg to 150 mg, 5 mg to 100 mg, 5 mg to 50 mg, 5 mg to 40 mg, 5 mg to 30 mg, 10 mg to 500 mg, 10 mg to 400 mg, 10 mg to 300 mg, 10 mg to 150 mg, 10 mg to 100 mg, 10 mg to 50 mg, 10 mg to 40 mg, 10 mg to 30 mg, 20 mg to 500 mg, 20 mg to 400 mg, 20 mg to 300 mg, 20 mg to 150 mg, 20 mg to 100 mg, 40 mg The dosage may be from 50 mg to 500 mg, 40 mg to 400 mg, 40 mg to 300 mg, 40 mg to 150 mg, 50 mg to 500 mg, 50 mg to 400 mg, 50 mg to 300 mg, 50 mg to 150 mg, 100 mg to 500 mg, 100 mg to 400 mg, 100 mg to 300 mg, or 100 mg to 150 mg. The pharmaceutical composition according to the present invention comprising microspheres comprising terzepatide or a pharmaceutically acceptable salt thereof and an early-release inhibitor according to the present invention may also be administered parenterally, for example, via subcutaneous injection.The pharmaceutical composition according to the present invention may be composed of a drug part containing microparticles including terzepatide or a pharmaceutically acceptable salt thereof and an early-release inhibitor, and a solvent part used to suspend the microparticles, and may be in the form of a dual-chamber syringe having the drug part in one chamber and the solvent part in the other chamber, or a prefilled syringe in which the drug part is suspended in the solvent part. When the composition is in the form of a prefilled syringe in which the drug part is suspended in the solvent part, the solvent part used may be an injectable oil containing medium-chain oil, mineral oil, etc.

[0068] In a specific embodiment, the sustained-release microspheres containing terzepatide or a pharmaceutically acceptable salt thereof and an early-release inhibitor included in the pharmaceutical composition according to the present invention have a high drug content relative to the content of the microspheres, while suppressing the initial excessive release of the drug that may cause fatal side effects and exhibiting high bioavailability to sufficiently exhibit the efficacy as a GIP analog for a desired period of time, and are useful for the prevention or treatment of diabetes, specifically type 2 diabetes, beta-cell dysfunction, hypertension, hyperlipidemia, obesity, non-alcoholic steatohepatitis, Alzheimer's disease, or Parkinson's disease.

[0069]

[0070] In another aspect, the present invention provides a method for preparing sustained-release microspheres containing terzepatide or a pharmaceutically acceptable salt thereof and an early-release inhibitor.

[0071] In another aspect, the present invention provides a method for preparing sustained-release microspheres having significantly suppressed initial release despite containing a high content of terzepatide or a pharmaceutically acceptable salt thereof.

[0072] Hereinafter, a method for manufacturing a sustained-release microparticle injection containing the present invention's terzepatide or a pharmaceutically acceptable salt thereof and an early-release inhibitor is specifically described.

[0073] The sustained-release microsphere injection containing terzepatide or a pharmaceutically acceptable salt thereof and an early-release inhibitor according to the present invention can be manufactured using, for example, “emulsion solvent extraction and evaporation method,” but the manufacturing method is not limited thereto.

[0074] As one embodiment of the specific manufacturing method, the present invention provides a method for manufacturing sustained-release microspheres with an O / W emulsion comprising the following steps:

[0075] (a) A step of preparing an oil phase (O phase) in which terzepatide or a pharmaceutically acceptable salt thereof and one or more biodegradable polymers are dissolved in an organic solvent as a dispersion phase;

[0076] (b) a step of preparing a continuous phase (W phase) by adding an early release inhibitor to an aqueous solution containing a surfactant, and adding the dispersed phase of step (a) to prepare a dispersed phase in an emulsion state;

[0077] (c) a step of extracting and evaporating an organic solvent from the dispersed phase of the emulsion state prepared in step (b) into a continuous phase (W phase) to form microspheres; and

[0078] (d) Step of recovering the microspheres.

[0079]

[0080] In another aspect, the present invention provides a method for preparing a western-type microsphere with a W / O / W emulsion comprising the following steps:

[0081] (a') a step of preparing a water phase (W1 phase) by dissolving terzepatide or a pharmaceutically acceptable salt thereof in an aqueous solution, preparing an oil phase (O phase) by dissolving one or more biodegradable polymers in an organic solvent, and preparing a first W1 / O emulsion by mixing the water phase (W1 phase) and the oil phase (O phase) as a dispersion phase;

[0082] (b') A step of preparing a continuous phase (W2 phase) by adding an early release inhibitor to an aqueous solution containing a surfactant, and adding the dispersed phase of step (a') to prepare a dispersed phase in a secondary W1 / O / W2 emulsion state;

[0083] (c') A step of forming microspheres by extracting and / or evaporating an organic solvent from the dispersed phase of the secondary W1 / O / W2 emulsion state of step (b') into a continuous phase (W2 phase);

[0084] (d') Step of recovering the microspheres.

[0085]

[0086] In another aspect, the pH of the continuous phase used in the above manufacturing methods may be 7 or higher.

[0087] In the manufacture of sustained-release microspheres containing terzepatide or a pharmaceutically acceptable salt thereof and an early-release inhibitor according to the present invention, the following biodegradable polymers may be used to suppress excessive early release of terzepatide or a pharmaceutically acceptable salt thereof while containing a high amount of terzepatide or a pharmaceutically acceptable salt thereof relative to the weight of the microspheres, and to release at a constant concentration for a desired long period of time, for example, for 1 month or more, 3 months or more, 1 month to 2 months, 1 month to 3 months, 1 month to 4 months, 1 month to 5 months, 1 month to 6 months, 2 months to 6 months, 2 months to 5 months, 2 months to 4 months, 2 months to 3 months, 3 months to 5 months, or 3 months to 4 months. Specifically, polylactide (PLA), polyglycolide (PGA), polylactide-co-glycolide (PLGA), polydioxanone, polycaprolactone (PCL), polylactide-co-glycolide-co-caprolactone (PLGC), polylactide-co-hydroxymethyl glycolide (PLGMGA), polyalkylcarbonate, polytrimethylenecarbonate (PTMC), polylactide-co-trimethylenecarbonate (PLTMC), polyhydroxybutyric acid (Polyhydroxybutyric acid) Polyhydroxybutyrate-co-hydroxyvalerate (PHBV),It is preferable to use at least one polymer, preferably at least two polymers, selected from the group consisting of a polymer selected from the group consisting of polyorthoester, polyanhydride, polyanhydride-co-imide, polypropylene fumarate, pseudo polyaminoacid, polyalkyl cyanoacrylate, polyphosphazene, polyphosphoester, polysaccharide and poly(butylene succinate lactide) (PBSLA), a simple mixture of two or more of the above-mentioned polymers, a copolymer of the above-mentioned polymer and polyethylenglycol (PEG), and a polymer-sugar complex in which the above-mentioned polymer or copolymer is bound to a sugar. In a specific embodiment, the manufacturing method according to the present invention may use poly(lactide-co-glycolide) and / or polylactide polymer as the biodegradable polymer.

[0088] In the present invention, the two or more different biodegradable polymers may include two or more polymers having different repeating units constituting the polymers, and two or more polymers having different molar ratios of the repeating units when including two or more repeating units. As an example, the microspheres may be a mixture of microspheres including poly-lactide-co-glycolide and microspheres including polylactide polymer, or microspheres including both poly-lactide-co-glycolide and polylactide polymer.

[0089] In addition, as a specific example, when there are two types of biodegradable polymers that are different from each other, the content ratio of these biodegradable polymers may be, but is not limited to, a weight ratio of 0.5:10 to 10:0.5, 0.5:8 to 8:0.5, 1:10 to 10:1, 1:4 to 4:1, 1:3 to 3:1, or 1:2 to 2:1.

[0090] Additionally, unless otherwise defined, the content of the biodegradable polymer described in the microspheres according to the present invention may be applied as is.

[0091] In a more specific embodiment, when polylactide-co-glycolide is used as two or more biodegradable polymers to prepare sustained-release microspheres containing terzepatide or a pharmaceutically acceptable salt thereof and an early-release inhibitor according to the present invention, at least one biodegradable polymer having an intrinsic viscosity of 0.16 dL / g to 0.45 dL / g may be included.

[0092] For the above polylactide-co-glycolide, the molar ratio of lactide to glycol in the copolymer may be 40:60 to 90:10, 45:55 to 85:15, or 50:50 to 75:25, for example, 45:55, 50:50, 75:25, or 85:15.

[0093] Additionally, unless otherwise defined, the content of the biodegradable polymer described in the microspheres according to the present invention may be applied as is.

[0094] In step (a) or (a') of the above specific manufacturing method, the organic solvent used to dissolve at least one biodegradable polymer is at least one organic solvent. In addition, the organic solvent may be a mixed organic solvent obtained by mixing two or more organic solvents. In a specific embodiment, the mixed solvent may be a mixed solvent of an organic solvent that is miscible with water and an organic solvent that is immiscible with water. In this case, it is preferable to use at least 50% (v / v) or more, 60% (v / v) or more, 50 to 99.9% (v / v) or more, 50 to 90% (v / v) or more, 50 to 80% (v / v) or more, 50 to 70% (v / v) or more, 60 to 90% (v / v) or more, or 60 to 80% (v / v) or more of the organic solvent that is immiscible with water. By utilizing the property of the organic solvent not to be miscible with water, an emulsion can be formed by homogeneously mixing the dispersed phase in the continuous phase containing the surfactant in step (b) or (b') described below. The type of the organic solvent that dissolves one or more biodegradable polymers is not particularly limited, but preferably, a mixed solvent of one or more solvents selected from the group consisting of dichloromethane, chloroform, ethyl acetate, methyl ethyl ketone, acetone, acetonitrile, dimethyl sulfoxide, dimethylformamide, N-methylpyrrolidone, acetic acid, methyl alcohol, ethyl alcohol, propyl alcohol, and benzyl alcohol, more preferably, one solvent selected from dichloromethane and ethyl acetate and one or more organic solvents selected from dimethyl sulfoxide, N-methylpyrrolidone, methyl alcohol, and acetic acid can be used. In one embodiment, a mixture of dichloromethane and acetic acid (glacial acetic acid) may be used as the organic solvent.

[0095] The method for homogeneously mixing the dispersed phase and the continuous phase containing the surfactant in the above step (b) or (b') is not particularly limited, but may be performed using a high-speed stirrer, an inline mixer, a membrane emulsion method, a microfluidic emulsion method, an ultrasonic mixer, or a static mixer, alone or in combination of two or more. When forming an emulsion using a high-speed stirrer, an inline mixer, an ultrasonic mixer, or a static mixer, it is difficult to obtain a uniform emulsion, so it is preferable to additionally perform a sieving process, etc. between steps (c) and (d) described below, or between steps (c') and (d').

[0096] The type of surfactant used in the above step (b) or (b') is not particularly limited, and any surfactant that can help the dispersed phase form a stable droplet dispersed phase within the continuous phase can be used. The surfactant may be polyvinyl alcohol, methylcellulose, polyvinylpyrrolidone, carboxymethylcellulose, lecithin, gelatin, polyoxyethylene sorbitan fatty acid ester, polyoxyethylene castor oil derivative, etc., which can be used alone or in combination of two or more.

[0097] In the above step (b) or (b'), the content of the surfactant in the continuous phase containing the surfactant may be 0.01 w / v% to 20 w / v%, preferably 0.03 w / v% to 18 w / v%, 0.05 w / v% to 15 w / v%, 0.07 w / v% to 10 w / v% or 0.1 w / v% to 5 w / v%, based on the total volume of the continuous phase including the surfactant. When the content of the surfactant is less than 0.01 w / v%, a dispersed phase or emulsion in the form of droplets may not be formed in the continuous phase, and when the content of the surfactant exceeds 20 w / v%, after fine particles are formed in the continuous phase due to an excessive amount of surfactant, it may be difficult to remove the surfactant.

[0098] The continuous phase used in the above step (b) or (b') may be an aqueous solution containing a surfactant and an early-release inhibitor. In addition, the continuous phase may be used by adding the early-release inhibitor to an aqueous solution containing a surfactant to reach the final concentration.

[0099] Depending on the use of the above early release inhibitor, the early release of microparticles containing a high content of drug can be controlled, and a substance capable of setting the pH of the continuous phase to 7.0 or higher can be used as the early release inhibitor.

[0100] The type of the above early-release inhibitor is not particularly limited, and any basic salt that can be dissolved in a continuous phase and maintained at a pH of 7.0 or higher can be used. The above early-release inhibitor may be at least one substance selected from among phosphate salts, hydroxide salts, phosphide salts, phosphite salts, carbonate salts, bicarbonate salts, chromate salts, dichromate salts, oxides, oxalate salts, silicate salts, sulfate salts, sulfide salts, sulfite salts, tartrate salts, tetraborate salts, thiosulfate salts, arsenate salts, arsenite salts, citrate salts, ferricyanide salts, and nitride salts of alkali metals, alkaline earth metals, or ammonium.

[0101] In a specific embodiment, the early release inhibitor may be at least one selected from the group consisting of phosphate salts of two or more alkali metals, carbonate salts of one or more alkali metals, bicarbonate salts of one or more alkali metals, and phosphate salts of two or more ammoniums, but is not limited thereto.

[0102] In a more specific embodiment, the phosphate salts of the two or more alkali metals are disodium phosphate (Na2HPO4) or dipotassium phosphate (K2HPO4), the carbonate salts of the one or more alkali metals are sodium bicarbonate (NaHCO3) or sodium carbonate (Na2CO3), and the phosphate salts of the two or more ammoniums are diammonium phosphate ((NH4)2HPO4), and these may be used alone or in combination of two or more.

[0103] The final concentration of the early release inhibitor in the above continuous phase may be 0.1 to 5.0 (w / v)%, preferably 0.1 to 4.0 (w / v)%, more preferably 0.2 to 4.0 (w / v)%, still more preferably 0.3 to 3.5 (w / v)%, particularly preferably 0.4 to 3.0 (w / v)%, and particularly more preferably 0.5 to 2.5 (w / v)%.

[0104] If the content of the initial release inhibitor exceeds 5.0 w / v%, the emulsion droplets may burst during the manufacture of microspheres. Conversely, if it is lower than 0.1 w / v%, the initial release of microspheres containing a high content of terzepatide may not be sufficiently suppressed.

[0105] When the above early release inhibitor is included in the continuous phase during the manufacture of microspheres, the early release from microspheres containing 12 (w / w)% or more of terzepatide can be reduced preferably to 10% or less, more preferably to 8% or less, and most preferably to 5% or less.

[0106] The continuous phase used in the above step (b) or (b') may further include at least one selected from the group consisting of methyl alcohol, ethyl alcohol, propyl alcohol, and ethyl acetate in order to control the extraction rate of the organic solvent from the dispersed phase in the emulsion state.

[0107] The early release inhibitor may be added at the time of preparing the continuous phase in the above step (b) or (b'), and the early release inhibitor may also be added at any time during the supply of the continuous phase in the above step (c) or (c'), and the method of addition is not limited.

[0108]

[0109] Additionally, the pH of the continuous phase may be, but is not limited to, 7.0 or more, 7.2 or more, 7.4 or more, 8.0 or more, 8.5 or more, 9.0 or more, 7.0 to 9.0, or 7.0 to 8.5. When the pH of the continuous phase is adjusted within the above range, the bioavailability of microspheres containing terzepatide or a pharmaceutically acceptable salt thereof may be further increased.

[0110] In the above step (c) or (c'), when the emulsion including the dispersed phase in the form of droplets and the continuous phase containing the surfactant is maintained or stirred at a temperature below the boiling point of the organic solvent for a certain period of time, for example, 2 to 48 hours, the organic solvent can be extracted as a continuous phase from the dispersed phase, which is the droplet-shaped terzepatide or a pharmaceutically acceptable salt thereof and a polymer solution. A portion of the organic solvent extracted as a continuous phase can be evaporated from the surface. As the organic solvent is extracted and evaporated from the droplet-shaped terzepatide or a pharmaceutically acceptable salt thereof and a polymer solution, the droplet-shaped dispersed phase can be solidified to form microspheres.

[0111] In order to further efficiently remove the organic solvent in step (c) or (c'), the temperature of the continuous phase may be heated for a certain period of time. The heating temperature is not limited and can be appropriately adjusted by a person skilled in the art depending on the organic solvent used. For example, when dichloromethane is used as the organic solvent, the heating may be applied so as to maintain the temperature at 30°C or higher, 40°C or higher, 45°C or higher, 30 to 50°C, 40 to 50°C, or 45°C.

[0112] In the above step (d) or (d'), the method for recovering microspheres containing terzepatide or a pharmaceutically acceptable salt thereof and an early-release inhibitor can be performed using various known techniques, for example, methods such as filtration or centrifugation can be used.

[0113] Between the above steps (c) and (d) or between steps (c') and (d'), the remaining surfactant can be removed through filtration and washing, and then filtered again to recover the microspheres.

[0114] The washing step to remove the remaining surfactant can be typically performed using water, and the washing step can be repeated several times.

[0115] Additionally, as described above, a sieving process may be additionally employed between steps (c) and (d) or between steps (c') and (d') to obtain uniform microspheres. The sieving process may be performed using known techniques, and microspheres of uniform size may be obtained by filtering out small and large particles using sieves of different sizes.

[0116] The manufacturing method of the present invention can obtain finally dried microparticles by drying the obtained microparticles using a conventional drying method after the step (d) or step (d') or after the filtering and washing step.

[0117] In addition to the above, all matters including terzepatide, early-release inhibitors, biodegradable polymers and their contents that are not separately defined may be applied as defined in the above pharmaceutical composition.

[0118] According to the manufacturing method of the present invention, a sustained-release microsphere injection containing terzepatide or a pharmaceutically acceptable salt thereof, which has high bioavailability and maintains an effective concentration for a desired period of time without abrupt, transient release of the drug, can be manufactured. In addition, a sustained-release microsphere injection containing terzepatide or a pharmaceutically acceptable salt thereof in uniform particles with good dosing capacity and an early-release inhibitor can be manufactured.

[0119] The sustained-release microspheres according to the present invention may be blended with two or more types of drug microspheres containing the same drug but differing in at least one of their compositions and manufacturing conditions. Blending microspheres containing two or more types of drug microspheres may be performed for purposes such as optimizing the drug release profile and controlling the release period.

[0120] Specifically, the different compositions and manufacturing conditions may be at least one selected from the group consisting of, but are not limited to, the amount of drug used, the type of polymer, the particle size distribution (e.g., average particle size), circularity, the amount of polymer used, the type and amount of dispersed phase solvent, the type and amount of co-solvent, the type and amount of continuous phase, the solidification temperature and time, and the theoretical content of the drug.

[0121] The above microparticle blending may be, for example, mixing one or more different drug microparticles of different compositions and manufacturing conditions at a specific ratio.

[0122] Specifically, when blending microspheres, the mixing ratio (weight ratio or ratio of microsphere number) can be appropriately adjusted by considering the bioavailability of the effective ingredients of each microsphere.

[0123] As a specific example, the two different drug microspheres may be drug microspheres having different components and composition ratios (hereinafter, drug microspheres having different compositions) and / or drug microspheres having different drug release characteristics, and for example, at least one selected from the group consisting of the type of polymer of the microsphere, the polymer content, the drug content, etc. may be different. The type of polymer of the microspheres may be different in at least one selected from the group consisting of the repeating unit of the polymer, the terminal group of the polymer, the molecular weight of the polymer, the intrinsic degree of the polymer, etc.

[0124] The above microsphere blending can be achieved by separately manufacturing and mixing the microspheres, or by manufacturing them in a single manufacturing process. Specifically, an O / W emulsion method for manufacturing the microsphere blending in a single manufacturing process can be produced by, as an example, including the following steps 1 to 4.

[0125] A step of separately preparing two or more types of dispersed solutions by dissolving biodegradable polymers and drugs having different compositions in organic solvents (step 1);

[0126] A step of forming an emulsion of two or more dispersed phases by injecting two or more types of dispersed phases prepared in the above step 1 into an aqueous solution (continuous phase) containing a surfactant (step 2);

[0127] A step of forming microspheres by extracting and evaporating the organic solvent from the dispersed phase emulsion prepared in step 2 to the continuous phase (step 3); and

[0128] It may include a step of recovering the microspheres (step 4) after the above step 3.

[0129] Specifically, a W / O / W emulsion method for manufacturing microparticle blending in one manufacturing process can be manufactured by including the following steps 1 to 4 as an example.

[0130] A step (step 1) of preparing a water phase (W1 phase) in which a drug is dissolved in an aqueous solution, preparing two or more oil phases (O phase) by dissolving biodegradable polymers having different compositions in organic solvents, and separately preparing a dispersed phase solution by mixing the water phase (W1 phase) and two or more oil phases (O phase);

[0131] A step of forming an emulsion of two or more dispersed phases by injecting two or more dispersed phases prepared in the above step 1 into an aqueous solution (W2 phase, continuous phase) containing a surfactant (step 2);

[0132] A step (step 3) of forming microspheres by extracting and evaporating the organic solvent from the dispersed emulsion prepared in step 2 toward the continuous phase (W2 phase); and

[0133] It may include a step of recovering the microspheres (step 4) after the above step 3.

[0134] [Example]

[0135] Hereinafter, the present invention will be described in more detail with reference to the following manufacturing examples. However, the following manufacturing examples are merely illustrative of the present invention, and the content of the present invention is not limited to the following manufacturing examples.

[0136] Examples 1-1 to 1-3 (O / W preparation): Preparation of biodegradable polymer microspheres containing terzepatide and an early-release inhibitor

[0137] Terzepatide (manufacturer: Zhejiang Peptides Biotech Co., Ltd, China) was used as the drug, and RG653H and RG753H (manufacturer: Evonik, Germany) were used as biodegradable polymers at a weight ratio of 1:1 and weighed so that the batch size was 0.5 to 1.5 g (Examples 1-1 and 1-2 had a batch size of 0.5 g, and Example 1-3 had a batch size of 1.5 g). The drug and polymer were homogeneously dissolved in a mixed solvent of dichloromethane (DCM) and glacial acetic acid as a co-solvent, and an oil phase (O phase) was prepared as a dispersed phase.

[0138] Na2HPO4 (Disodium phosphate) was added as an early release inhibitor to a 0.1 (w / v)% polyvinyl alcohol (viscosity: 4.8–5.8 mPa.s) aqueous solution as a continuous phase (W phase) to a final concentration of 2.0 (w / v)%.

[0139] After connecting the continuous phase to an emulsifying device equipped with a 40 μm diameter porous membrane, the prepared dispersed phase was injected into the porous membrane together with the continuous phase. An emulsion containing biodegradable polymer microdroplets containing terzepatide was prepared, and the suspension was placed in a preparation vessel and stirred at a speed of 200 to 300 rpm.

[0140] The temperature of the preparation vessel was maintained at 25°C, and after the dispersion phase was injected, the temperature of the suspension was maintained at 40°C for 3 hours to remove the organic solvent. After cooling to 25°C, the solution was filtered, and the residual polyvinyl alcohol was removed with triple-distilled water, followed by freeze-drying.

[0141]

[0142] Example No. T / L % Polymer type Polymer amount (g) Terzepatide amount (g) DCM amount (g) Glacial acetic acid amount (g) Early release inhibitor and concentration 1-115 RG653H: RG753H = 1:10.4 25 0.07 5 5.24 2.812 (w / v) % Na2HPO4 1-220 RG653H: RG753H = 1:10.4 0 0.10 0 4.9 3 2.76 2 (w / v) % Na2HPO4 1-315 RG653H: RG753H = 1:11.2 7 5 0.22 5 15.7 0 8.5 12 (w / v) % Na2HPO4

[0143] * T / L:Target Loading

[0144] Examples 2-1 to 2-9 (O / W preparation): Preparation of biodegradable polymer microspheres containing terzepatide and an early-release inhibitor (differences in the type or concentration of the early-release inhibitor)

[0145] Terzepatide (manufacturer: Chengdu Shengnuo Biopharm Co., Ltd, China) was used as the drug, and biodegradable polymers RG653H and RG753H (manufacturer: Evonik, Germany) were used at a weight ratio of 1:1 and weighed so that the batch size was 0.5 g (target loading 20%). The drug and polymer were homogeneously dissolved in a mixed solvent of dichloromethane (DCM) solvent and glacial acetic acid co-solvent to prepare an oil phase (O phase) as the dispersed phase.

[0146] The initial release inhibitor was added to a 0.1 (w / v)% polyvinyl alcohol (viscosity: 4.8–5.8 mPa.s) aqueous solution as a continuous phase (W phase) to reach the final concentration.

[0147] After connecting the continuous phase to an emulsifying device equipped with a 40 μm diameter porous membrane, the prepared dispersed phase was injected into the porous membrane together with the continuous phase. An emulsion containing biodegradable polymer microdroplets containing terzepatide was prepared, and the suspension was placed in a preparation vessel and stirred at a speed of 200 to 300 rpm.

[0148] The temperature of the preparation vessel was maintained at 25°C, and after the dispersion phase was injected, the temperature of the suspension was maintained at 40°C for 3 hours to remove the organic solvent. After cooling to 25°C, the solution was filtered, and the residual polyvinyl alcohol was removed with triple-distilled water, followed by freeze-drying.

[0149]

[0150] Example No. Polymer type Polymer amount (g) Terzepatide amount (g) DCM amount (g) Glacial acetic acid amount (g) Initial release inhibitor and concentration (w / v) % 2-1RG653H:RG753H = 1:10.4000.1004.932.941% K2HPO4 2-2RG653H:RG753H = 1:10.4000.1004.933.001% Na2CO3 2-3RG653H:RG753H = 1:10.4000.1004.933.001% (NH4)2HPO4 2-4RG653H:RG753H = 1:10.4000.1004.933.001% NaHCO32-5RG653H:RG753H=1:10.4000.1004.932.941% Na2HPO42-6RG653H:RG753H=1:10.4000.1004.933.002% K2HPO42-7RG653H:RG753H=1:10.4000.1004.933.022% Na2CO32-8RG653H:RG753H=1:10.4000.1004.933.032% (NH4)2HPO42-9RG653H:RG753H=1:10.4000.1004.933.032% NaHCO3

[0151] Examples 3-1 to 3-2 (O / W preparation): Preparation of biodegradable polymer microspheres containing terzepatide and an early-release inhibitor (differences in polymer types)

[0152] Terzepatide (manufacturer: Chengdu Shengnuo Biopharm Co., Ltd, China) was used as the drug, and RG503H or RG203H (manufacturer: Evonik, Germany) was used as the biodegradable polymer, and the batch size was weighed to be 0.5 g (target loading 20%). The drug and polymer were homogeneously dissolved in a mixed solvent of dichloromethane (DCM) solvent and glacial acetic acid co-solvent, and an oil phase (O phase) was prepared as the dispersed phase.

[0153] Na2HPO4 (Disodium phosphate) was added as an early release inhibitor to a 0.1 (w / v)% polyvinyl alcohol (viscosity: 4.8–5.8 mPa.s) aqueous solution as a continuous phase (W phase) to a final concentration of 2.0 (w / v)%.

[0154] After connecting the continuous phase to an emulsifying device equipped with a 40 μm diameter porous membrane, the prepared dispersed phase was injected into the porous membrane together with the continuous phase. An emulsion containing biodegradable polymer microdroplets containing terzepatide was prepared, and the suspension was placed in a preparation vessel and stirred at a speed of 200 to 300 rpm.

[0155] The temperature of the preparation vessel was maintained at 25°C, and after the dispersion phase was injected, the temperature of the suspension was maintained at 40°C for 3 hours to remove the organic solvent. After cooling to 25°C, the solution was filtered, and the residual polyvinyl alcohol was removed with triple-distilled water, followed by freeze-drying.

[0156]

[0157] Example No. Polymer type Polymer amount (g) Terzepatide amount (g) DCM amount (g) Glacial acetic acid amount (g) Early release inhibitor and concentration 3-1RG503H0.4000.1004.933.002(w / v)% Na2HPO4 3-2R203H0.4000.1004.933.062(w / v)% Na2HPO4

[0158] Examples 4-2 to 4-3 (W / O / W preparation): Preparation of biodegradable polymer microspheres containing terzepatide and an early-release inhibitor (differences in drug loading content or polymer type)

[0159] The first phase (W1) was prepared by dissolving terzepatide (Chengdu Shengnuo Biopharm Co., Ltd., China) as a drug in triple-distilled water. The oil phase (O) was prepared by dissolving biodegradable polymers RG653H and RG753H (manufacturer: Evonik, Germany) in a 1:1 weight ratio or RG503H (manufacturer: Evonik, Germany) alone in dichloromethane (DCM). The first W1 / O emulsion (dispersed phase) was prepared by dispersing the water phase in the oil phase using a homogenizer.

[0160] Na2HPO4 (Disodium phosphate) was added as an initial release inhibitor to a 0.1 (w / v) % polyvinyl alcohol (viscosity: 4.8–5.8 mPa.s) aqueous solution as a continuous phase (W2 phase) to a final concentration of 2.0 (w / v)%.

[0161] After connecting the continuous phase to an emulsifying device equipped with a porous membrane having a diameter of 40 μm, the prepared dispersed phase was injected into the porous membrane together with the continuous phase. A secondary W1 / O / W2 emulsion in which biodegradable polymer microdroplets containing terzepatide were dispersed was prepared, and the suspension was placed in a preparation vessel and stirred at a speed of 200 to 300 rpm.

[0162] The temperature of the preparation vessel was maintained at 25°C, and after the dispersion phase injection was completed, the suspension temperature was maintained at 40°C for 3 hours to remove the organic solvent. After cooling to 25°C, the solution was filtered to remove the remaining polyvinyl alcohol with triple-distilled water, and freeze-dried.

[0163] Example No. T / L % Polymer type Polymer amount (g) Terzepatide amount (g) DCM amount (g) DW:DCM Weight ratio Initial release inhibitor and concentration 4-220RG653H:RG753H=1:10.4000.1007.61:10.42(w / v)% Na2HPO4 4-330RG503H0.3500.15011.31:9.32(w / v)% Na2HPO4

[0164] Comparative Example 1 (O / W method): Preparation of biodegradable polymer microspheres containing terzepatide without initial release inhibitor

[0165] 0.045 g of terzepatide (manufacturer: Zhejiang Peptides Biotech Co., Ltd, China) was used as the drug, and 0.255 g of biodegradable polymers RG653H and RG753H (manufacturer: Evonik, Germany) were used at a weight ratio of 1:1, and weighed so that the batch size was 0.3 g (target loading 15%). Dichloromethane (DCM) was used as the solvent for preparing the dispersed phase, and glacial acetic acid was used as a cosolvent to homogeneously dissolve it.

[0166] The continuous phase used 2,000 ml of 0.1% polyvinyl alcohol (viscosity: 4.8–5.8 mPa.s) aqueous solution.

[0167] After connecting the continuous phase to an emulsifying device equipped with a 40 μm diameter porous membrane, the prepared dispersed phase was injected into the porous membrane together with the continuous phase. An emulsion containing biodegradable polymer microdroplets containing terzepatide was prepared, and the suspension was placed in a preparation vessel and stirred at a speed of 200 to 300 rpm.

[0168] The temperature of the preparation vessel was maintained at 25°C, and after the dispersion phase was injected, the temperature of the suspension was maintained at 40°C for 3 hours to remove the organic solvent. After cooling to 25°C, the solution was filtered, and the residual polyvinyl alcohol was removed with triple-distilled water, followed by freeze-drying.

[0169] Comparative Example No. Polymer TypePolymer Amount Used (g)Terzepatide Amount Used (g)DCM Amount Used (g)Glacial Acetic Acid Amount Used (g)1RG653H:RG753H=1:10.2550.0453.11.69

[0170] Experimental Example 1. Measurement of the amount of terzepatide loaded into microspheres.

[0171] To measure the loading amount of terzepatide in the microspheres manufactured in the above examples and comparative examples, 10 mg of microspheres were completely dissolved in DMSO. 20 μL of the diluted solution was injected into HPLC and measured at a detection wavelength of 280 nm. The column used in this experimental example was ZORBAX 300SB-C18, 5 μm, 4.6 x 150 mm, and the mobile phase was a mixture of acetonitrile containing 0.1% (w / w) trifluoroacetic acid and 0.1% (w / w) trifluoroacetic acid aqueous solution in a ratio of 40:60 (v / v).

[0172] Encapsulation rate (%)Drug content (wt%)Example 1-174.8011.22Example 1-275.7015.14Example 1-377.2011.58Example 2-155.1211.02Example 2-257.4711.49Example 2-361.9312.39Example 2-453.9010.78Example 2-555.1211.02Example 2-655.0411.01Example 2-765.7413.15Example 2-863.0112.60Example 2-959.1111.82Example 3-157.0611.41Example 3-251.2510.25Example 4-270.6514.13Example 4-376.5522.97Comparative Example 1103.2015.48

[0173] As shown in Table 6,

[0174] Looking at the results of Examples 1-1 to 1-3 manufactured by the O / W method, it can be confirmed that the encapsulation rate tends to be maintained at 70% or more up to T / L 20%.

[0175] When manufacturing with the O / W method, looking at the results of Examples 2-1 to 2-9 with different types or concentrations of early release inhibitors, it can be confirmed that the encapsulation rate tends to be maintained between 50 and 70%.

[0176] When manufacturing with the O / W method and looking at the results of Examples 3-1 and 3-2 with different types of polymers, it can be confirmed that the encapsulation rate tends to be maintained between 50 and 70%.

[0177] Looking at the results of Examples 4-2 and 4-3 in which the drug loading content or polymer type was changed in the W / O / W formulation, it can be confirmed that the encapsulation rate tends to be maintained at 70% or more up to T / L 30%.

[0178]

[0179] Experimental Example 2. In vitro measurement of initial drug release from terzepatide microspheres

[0180] To confirm the initial drug release of the microspheres manufactured in the above examples and comparative examples, the following experiment was conducted. 10 mg of microspheres were placed in an HDPE wide-mouth bottle, filled with 50 mL of a release test solution, and stored in a 37°C incubator. After 24 hours, 1 mL of the test solution was taken, centrifuged, and the supernatant obtained was analyzed for the content and release rate of terzepatide using HPLC under the same analysis conditions as in Experimental Example 1. The release test solution used in this measurement was a pH 7.4 PBS solution containing sodium dodecyl sulfate and sodium azide.

[0181] In vitro Initial Release Rate (%, 1-day) Example 1-11.60 Example 1-22.94 Example 1-31.85 Example 2-11.74 Example 2-23.55 Example 2-41.66 Example 2-52.03 Example 2-61.28 Example 2-71.85 Example 2-82.48 Example 2-91.12 Example 3-14.13 Example 3-23.57 Example 4-27.75 Comparative Example 144.59

[0182] As shown in Table 7, it was confirmed that the initial drug release from microspheres containing terzepatide was significantly reduced when an early-release inhibitor was included in the continuous phase during the manufacture of microspheres. Meanwhile, in the case of Comparative Example 1, which did not include an early-release inhibitor, the first-day release rate was 44.59%, confirming the occurrence of an initial burst.

[0183]

[0184] Experimental Example 3. Morphological Analysis Using an Electron Microscope

[0185] The morphological characteristics of the microspheres according to the present invention were analyzed using an electron microscope. The experimental procedure is as follows. 5 mg of the microspheres manufactured in the examples and manufacturing examples were placed on an aluminum stub with a carbon tape attached and coated with platinum using an ION-COATER (COXEM, Korea). The aluminum stub was mounted on a scanning electron microscope (COXEM EM-30, Korea), and the morphological characteristics of the microspheres were observed at an acceleration voltage of 10 to kV, and the results are shown in Figs. 1a (Example 1-1) and 1b (Comparative Example 1).

[0186]

[0187] Figure 1a is a scanning electron microscope photograph confirming the morphological characteristics of microspheres manufactured in Example 1-1.

[0188] Figure 1b is a scanning electron microscope photograph confirming the morphological characteristics of the microspheres manufactured in Comparative Example 1.

[0189]

[0190] Experimental Example 4. In-vivo pharmacokinetic evaluation using rats

[0191] In order to evaluate the drug release profile of microspheres according to an embodiment of the present invention, the concentration of terzepatide in the blood was measured after administration to rats.

[0192] Microspheres were weighed to provide 3.6 mg / head (12.0 mg / kg) of terzepatide, dispersed in 0.5 mL of suspension, and subcutaneously injected into SD rats (Sprague-Dawley rats, 300 g). 0.5 mL of blood was collected at pre-scheduled times, and the blood terzepatide concentration was measured using HPLC.

[0193]

[0194] Experimental no. G2 G4 G6 G7 Example no. 1-11-2 Comparative example 11-3 T / L % 15 20 15 15 Dose (mg / head) 3.6 3.6 3.6 3.6 3.6 AUC norm (ng*day / mL) / (mg / head) 5 4 2 2.0 2 6 7 0.8 3 8 5 4.5 3 17 0.6 C max (ng / mL) 1 5 0 3.7 9 4.1 7 2 17.5 9 3 9.3

[0195] As shown in Table 8, it was confirmed that the bioavailability of the terzepatide microspheres manufactured in the examples was at a good level.

[0196]

[0197] Experimental Example 5. Single-dose subcutaneous pharmacokinetic study using Sprague-Dawley rats

[0198] In order to evaluate the potential of the microspheres of the present invention as a sustained-release therapeutic agent, the concentration of terzepatide in rat blood was measured by the following method.

[0199] Specifically, the dose of terzepatide was 3.6 mg / head. Microspheres were measured and dispersed in 0.5 mL of suspension, and then subcutaneously injected into SD rats. 0.25-0.5 mL of blood was collected at pre-scheduled intervals, and the blood concentration of terzepatide was measured using HPLC.

[0200]

[0201] Time(day)-Concetration (ng / mL)Time(day)Example no.Comparative example no.1-11-21-3100.00.00.00.00.25223.9548.2685.73791.41464.3994.1939.37217.5422.4111.4751.6243.67250.6205.5488.4391.110509.1102.4600.9151.214 1503.786.1202.962.217916.7113.7101.453.921189.1110.971.034.928321.6287.143.420.435486.5391.3169.328.242232.3116.699.814.94944.416.832.510.5

[0202] As shown in Table 9, the microspheres manufactured in the examples showed an excellent sustained-release profile, with no initial burst until day 1 and continuous release until day 49. On the other hand, the microspheres of Comparative Example 1, which did not contain an initial-release inhibitor, showed an initial burst until day 1, with most of the drug being released, and a minimal concentration being released after day 10.

[0203]

[0204] Experimental Example 6. Measurement of residual early-release inhibitor content in microparticles.

[0205] In order to measure the content of early release inhibitors in the microparticles manufactured in the above example, the residual amounts of sodium (Na) and phosphorus (P) in the microparticles were measured.

[0206] Specifically, 300 mg of microspheres were mixed with 6 mL of a nitric acid solution mixed 1:1 with ultrapure water and 3 mL of hydrogen peroxide, heated to above 100°C, and acid was added until the gas generated during the dissolution process changed from yellow to white. The sample obtained through this was weighed, dissolved in ultrapure water, and injected into an inductively coupled plasma optical emission spectrometer (ICP-OES) (Thermo Scientific Co., iCAP 6300 Duo, UK) and measured at a detection wavelength of 598.5 nm.

[0207] Example 3-2 Example 1-1 Example 4-2 Example 2-6 Early release inhibitor 2 (w / v) % Na2HPO4 2 (w / v) % Na2HPO4 2.0 (w / v) % Na2HPO4 2 (w / v) % K2HPO4 Polymer R20 3 HRG 653 H:RG 753 HRG 653 H:RG 753 HRG 653 H:RG 753 H Residual sodium (mg / kg) 388102121 - Residual phosphorus (mg / kg) 80354442

[0208] As shown in Table 10, the content of residual sodium and phosphorus according to the initial release inhibitor included in the continuous phase differs depending on the microparticle manufacturing conditions, and it was confirmed that the content of the initial release inhibitor remaining in the microparticles calculated from this was 50 ppm to 500 ppm based on sodium (Na) and 10 to 100 ppm based on phosphorus (P).

Claims

1. Contains sustained-release microspheres composed of terzepatide or a pharmaceutically acceptable salt thereof, an early-release inhibitor, and a biodegradable polymer. The above terzepatide or a pharmaceutically acceptable salt thereof is contained in an amount of 8 wt% or more as terzepatide based on the total weight of the microspheres, A pharmaceutical composition for preventing or treating diabetes, type 2 diabetes, beta-cell dysfunction, obesity, or non-alcoholic steatohepatitis, wherein the early-release inhibitor is contained in an amount of 5 ppm to 2000 ppm.

2. A pharmaceutical composition in accordance with claim 1, wherein the sustained-release microspheres containing terzepatide or a pharmaceutically acceptable salt thereof and an early-release inhibitor release less than 20% of terzepatide or a pharmaceutically acceptable salt thereof within 24 hours when administered in vivo.

3. A pharmaceutical composition in accordance with claim 1, wherein the sustained-release microspheres containing terzepatide or a pharmaceutically acceptable salt thereof and an early-release inhibitor release less than 15% of terzepatide or a pharmaceutically acceptable salt thereof within 24 hours when administered in vivo.

4. A pharmaceutical composition in accordance with claim 1, wherein the sustained-release microspheres containing terzepatide or a pharmaceutically acceptable salt thereof and an early-release inhibitor release less than 10% of terzepatide or a pharmaceutically acceptable salt thereof within 24 hours when administered in vivo.

5. In the first paragraph, the biodegradable polymer Polylactide (PLA), Polyglycolide (PGA), Polylactide-co-glycolide (PLGA), Polydioxanone, Polycaprolactone (PCL), Polylactide-co-glycolide-co-caprolactone (PLGC), Polylactide-co-hydroxymethyl glycolide (PLGMGA), Polyalkylcarbonate, Polytrimethylenecarbonate (PTMC), Polylactide-co-trimethylenecarbonate (PLTMC), Polyhydroxybutyric acid (PHB), A polymer selected from the group consisting of polyhydroxybutyrate-co-hydroxyvalerate (PHBV), polyorthoester, polyanhydride, polyanhydride-co-imide, polypropylene fumarate, pseudopolyaminoacid, polyalkyl cyanoacrylate, polyphosphazene, polyphosphoester, polysaccharide, and poly(butylene succinate lactide) (PBSLA); a copolymer or simple mixture of two or more of the selected polymers; a copolymer of the selected polymer and polyethylenglycol (PEG);A pharmaceutical composition comprising at least one selected from the group consisting of a polymer-sugar complex in which the selected polymer or copolymer is combined with a sugar.

6. A pharmaceutical composition according to claim 1, wherein the early release inhibitor is at least one substance selected from among phosphate salts, hydroxide salts, phosphide salts, phosphite salts, carbonate salts, chromate salts, dichromate salts, oxides, oxalate salts, silicate salts, sulfate salts, sulfide salts, sulfite salts, tartrate salts, tetraborate salts, thiosulfate salts, arsenate salts, arsenite salts, citrate salts, ferricyanide salts, and nitride salts of alkali metals, alkaline earth metals, or ammonium.

7. A pharmaceutical composition according to claim 1, wherein the average particle size of the microspheres containing the terzepatide or a pharmaceutically acceptable salt thereof and the early-release inhibitor is 5 μm to 100 μm.

8. A pharmaceutical composition according to claim 1, wherein the total weight of microspheres containing the entire tert-butyl ...

9. A pharmaceutical composition according to claim 1, wherein the intrinsic viscosity of the biodegradable polymer is 0.16 dL / g to 1.7 dL / g.

10. A pharmaceutical composition according to claim 1, wherein the microspheres further comprise at least one release-controlling agent selected from the group consisting of butyric acid, valeric acid, caproic acid, enanthic acid, caprylic acid, pelargonic acid, capric acid, undecylic acid, lauric acid, tridecylic acid, myristic acid, pentadecylic acid, palmitic acid, heptadecylic acid, stearic acid, nonadecylic acid, behenic acid, arachidic acid, isocrotonic acid, oleic acid, elaidic acid, sorbic acid, linoleic acid, arachidonic acid, benzoic acid, hydroxynaphthoic acid, napadicylic acid, naphthalene sulfonic acid, and pamoic acid. 11.(a) A step of preparing an oil phase (O phase) in which terzepatide or a pharmaceutically acceptable salt thereof and one or more biodegradable polymers are dissolved in an organic solvent as a dispersion phase; (b) a step of preparing a continuous phase (W phase) by adding an early release inhibitor to an aqueous solution containing a surfactant, and adding the dispersed phase of step (a) to prepare a dispersed phase in an emulsion state; (c) a step of extracting and evaporating an organic solvent from the dispersed phase of the emulsion state prepared in step (b) into a continuous phase (W phase) to form microspheres; and (d) a method for preparing microspheres with an O / W emulsion comprising terzepatide or a pharmaceutically acceptable salt thereof, an early-release inhibitor and a biodegradable polymer, comprising a step of recovering the microspheres. 12.(a') A step of preparing a first phase (W1 phase) by dissolving terzepatide or a pharmaceutically acceptable salt thereof in an aqueous solution, preparing an oil phase (O phase) by dissolving one or more biodegradable polymers in an organic solvent, and preparing a first W1 / O emulsion by mixing the water phase (W1 phase) and the oil phase (O phase) as a dispersion phase; (b') A step of preparing a continuous phase (W2 phase) by adding an early release inhibitor to an aqueous solution containing a surfactant, and adding the dispersed phase of step (a') to prepare a dispersed phase in a secondary W1 / O / W2 emulsion state; (c') a step of forming microspheres by extracting and / or evaporating the organic solvent from the dispersed phase of the second W1 / O / W2 emulsion state of the above step (b') into a continuous phase (W2 phase); and (d') A method for preparing microspheres with a W / O / W emulsion comprising terzepatide or a pharmaceutically acceptable salt thereof, an early-release inhibitor and a biodegradable polymer, comprising a step of recovering microspheres.

13. In any one of claims 11 to 12, the biodegradable polymer is polylactide (PLA), polyglycolide (PGA), polylactide-co-glycolide (PLGA), polydioxanone, polycaprolactone (PCL), polylactide-co-glycolide-co-caprolactone (PLGC), polylactide-co-hydroxymethyl glycolide (PLGMGA), polyalkylcarbonate, polytrimethylenecarbonate (PTMC), polylactide-co-trimethylenecarbonate ( A polymer selected from the group consisting of polyhydroxybutyric acid (PHB), polyhydroxybutyrate-co-hydroxyvalerate (PHBV), polyorthoester, polyanhydride, polyanhydride-co-imide, polypropylene fumarate, pseudo polyaminoacid, polyalkyl cyanoacrylate, polyphosphazene, polyphosphoester, polysaccharide and poly(butylene succinate lactide) (PBSLA); a copolymer or simple mixture of two or more of the above-mentioned selected polymers;A manufacturing method comprising at least one selected from the group consisting of a copolymer of the above-mentioned selected polymer and polyethylene glycol (polyethylenglycol, PEG); and a polymer-sugar complex in which the above-mentioned selected polymer or copolymer is combined with sugar.

14. A manufacturing method according to any one of claims 11 to 12, wherein the dispersed phase of step (a) or (a') further comprises at least one release controlling agent selected from the group consisting of butyric acid, valeric acid, caproic acid, enanthic acid, caprylic acid, pelargonic acid, capric acid, undecylic acid, lauric acid, tridecylic acid, myristic acid, pentadecylic acid, palmitic acid, heptadecylic acid, stearic acid, nonadecylic acid, arachidic acid, isocrotonic acid, oleic acid, elaidic acid, sorbic acid, linoleic acid, arachidonic acid, hydroxynaphthoic acid, napadicylic acid, and pamoic acid.

15. A manufacturing method according to any one of claims 11 to 12, wherein the organic solvent of step (a) or (a') is at least one organic solvent selected from the group consisting of dichloromethane, chloroform, ethyl acetate, methyl ethyl ketone, acetone, acetonitrile, dimethyl sulfoxide, dimethylformamide, n-methylpyrrolidone, acetic acid, methyl alcohol, ethyl alcohol, propyl alcohol, and benzyl alcohol.

16. A manufacturing method according to any one of claims 11 to 12, wherein the surfactant of step (b) or (b') is polyvinyl alcohol.

17. A manufacturing method according to any one of claims 11 to 12, wherein the continuous phase of step (b) or (b') further includes at least one selected from the group consisting of methyl alcohol, ethyl alcohol, propyl alcohol, and ethyl acetate.

18. A manufacturing method according to any one of claims 11 to 12, wherein the continuous phase of step (b) is used by adding an early release inhibitor to an aqueous solution containing a surfactant so that the final concentration is 0.1 to 5.0 (w / v)%.

19. A manufacturing method according to any one of claims 11 to 12, wherein the early release inhibitor is at least one selected from the group consisting of phosphate salts of two or more alkali metals, carbonate salts of one or more alkali metals, and phosphate salts of two or more ammoniums.

20. A manufacturing method according to any one of claims 11 to 12, wherein the pH of the continuous phase in step (b) or (b') is 7 or higher.

21. A manufacturing method according to any one of claims 11 to 12, wherein the sustained-release microspheres containing the manufactured terzepatide or a pharmaceutically acceptable salt thereof and an early-release inhibitor have a release rate of less than 15% of terzepatide or a pharmaceutically acceptable salt thereof within 24 hours when administered into a living body.

22. A manufacturing method according to any one of claims 11 to 12, wherein when the sustained-release microspheres containing the manufactured terzepatide or a pharmaceutically acceptable salt thereof and an early-release inhibitor are administered into a body, the release rate of terzepatide or a pharmaceutically acceptable salt thereof is less than 10% within 24 hours.

Citation Information

Patent Citations

  • Apparatus for jetting droplet

    KR1020230021950A

  • Positive electrode active material and preparing method for the same

    KR1020230162574A

  • A microsphere for sustained-release and a method for preparation thereof

    KR102212717B1

  • GIP / GLP1 agonist compositions

    US20220273762A1

  • Compositions and particles for payload delivery

    US20220275029A1